Extended Abstracts
Pharmacokinetics (PK) of a liposomal encapsulated fraction containing doxorubicin and of doxorubicin released from the liposomal capsule after intravenous infusion of Caelyx?/Doxil
R.A. Hilger, H. Richly, M. Grubert, C. Oberhoff, D. Strumberg, M.E. Scheulen and S. Seeber
Price
42.00 $
Volume 43 p. 588 - 589
Abstract
R.A. Hilger, H. Richly, M. Grubert, C. Oberhoff, D. Strumberg, M.E. Scheulen and S. Seeber
Extended Abstracts
Correlation of ERK-phosphorylation and toxicities in patients treated with the Raf kinase inhibitor BAY 43-9006
R.A. Hilger, S. Kredtke, M.E. Scheulen, S. Seeber and D. Strumberg
Price
42.00 $
Volume 42 p. 648 - 649
Abstract
R.A. Hilger, S. Kredtke, M.E. Scheulen, S. Seeber and D. Strumberg
Extended Abstracts
Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer
H. Richly, P. Kupsch, K. Passage, M. Grubert, R.A. Hilger, R. Voigtmann, B. Schwartz, E. Brendel, O. Christensen, C.G. Haase and D. Strumberg
Price
42.00 $
Volume 42 p. 650 - 651
Abstract
H. Richly, P. Kupsch, K. Passage, M. Grubert, R.A. Hilger, R. Voigtmann, B. Schwartz, E. Brendel, O. Christensen, C.G. Haase and D. Strumberg
Extended Abstracts
Pharmacokinetics of treosulfan in a myeloablative combination with cyclophosphamide prior to allogeneic hematopoietic stem cell transplantation
R.A. Hilger, J. Baumgart, M.E. Scheulen, R. Trenschel, D. Strumberg, S. Seeber and D.W. Beelen
Price
42.00 $
Volume 42 p. 654 - 655
Abstract
R.A. Hilger, J. Baumgart, M.E. Scheulen, R. Trenschel, D. Strumberg, S. Seeber and D.W. Beelen
Extended Abstracts
mproved viability of human tumor samples in a new oxygen-enriched solution
M. Heim, R.A. Hilger, S. Kredtke, D. Thyssen, F. Bach and D. Strumberg
Price
42.00 $
Volume 42 p. 659 - 660
Abstract
M. Heim, R.A. Hilger, S. Kredtke, D. Thyssen, F. Bach and D. Strumberg
Extended Abstracts
Circadian rhythm in the regulation of the MAP kinase pathway – pitfall in the determination of surrogate parameters?
R.A. Hilger, D. Díaz-Carballo, S. Bauer, S. Kredtke, M.E. Scheulen, S. Seeber and D. Strumberg
Price
42.00 $
Volume 41 p. 614 - 615
Abstract
R.A. Hilger, D. Díaz-Carballo, S. Bauer, S. Kredtke, M.E. Scheulen, S. Seeber and D. Strumberg
Extended Abstracts
Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006
M. Heim, M. Sharifi, R.A. Hilger, M.E. Scheulen, S. Seeber and D. Strumberg
Price
42.00 $
Volume 41 p. 616 - 617
Abstract
M. Heim, M. Sharifi, R.A. Hilger, M.E. Scheulen, S. Seeber and D. Strumberg
Extended Abstracts
A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors
H. Richly, P. Kupsch, K. Passage, M. Grubert, R.A. Hilger, S. Kredtke, D. Voliotis, M.E. Scheulen, S. Seeber and D. Strumberg
Price
42.00 $
Volume 41 p. 620 - 621
Abstract
H. Richly, P. Kupsch, K. Passage, M. Grubert, R.A. Hilger, S. Kredtke, D. Voliotis, M.E. Scheulen, S. Seeber and D. Strumberg
Extended Abstracts
Novel antitumoral compound isolated from Clusia rosea
D. Díaz-Carballo, S. Seeber, D. Strumberg and R.A. Hilger
Price
42.00 $
Volume 41 p. 622 - 623
Abstract
D. Díaz-Carballo, S. Seeber, D. Strumberg and R.A. Hilger
2008 CESAR: Annual Meeting – Extended Abstracts
Pharmacokinetic study of S-1
B. Mende, J. Krauss, D. Thyssen, S. Kredtke, M.E. Scheulen, D. Strumberg, A. Hanauske, L. Makris, P. Scigalla, P.D. Urrea and R.A. Hilger
Price
42.00 $
Volume 47 p. 65 - 67
Abstract
B. Mende, J. Krauss, D. Thyssen, S. Kredtke, M.E. Scheulen, D. Strumberg, A. Hanauske, L. Makris, P. Scigalla, P.D. Urrea and R.A. Hilger
Extended Abstract
ERK1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY43-9006
R.A. Hilger, S. Kredke, D. Hedley, J.G. Moeller, R.J. Bauer, W. Stellberg, S. Seeber, M.E. Scheulen and D. Strumberg
Price
42.00 $
Volume 40 p. 567 - 568
Abstract
R.A. Hilger, S. Kredke, D. Hedley, J.G. Moeller, R.J. Bauer, W. Stellberg, S. Seeber, M.E. Scheulen and D. Strumberg
Extended Abstract
Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors
D. Strumberg, D. Voliotis, J.-G. Moeller, R.A. Hilger, H. Richly, S. Kredtke, C. Beling, M.E. Scheulen and S. Seeber
Price
42.00 $
Volume 40 p. 580 - 581
Abstract
D. Strumberg1, D. Voliotis2, J.-G. Moeller2, R.A. Hilger1, H. Richly1, S. Kredtke1, C. Beling1, M.E. Scheulen1 and S. Seeber1
Extended Abstract
Neoadjuvant treatment of adenocarcinomas of the gastroesophageal junction and stomach – a feasibility trial combining cisplatin and docetaxel with either 5-fluorouracil or capecitabine
B. Schultheis, J. Riebeling, M. Allali, U. Bergmann, G. Kummer, U. Sendler, A. Tannapfel, A. Sendler and D. Strumberg
Price
42.00 $
Volume 48 p. 451 - 452
Abstract
Neoadjuvant treatment of adenocarcinomas of the gastroesophageal junction and stomach – a feasibility trial combining cisplatin and docetaxel with either 5-fluorouracil or capecitabine
B. Schultheis, J. Riebeling, M. Allali, U. Bergmann, G. Kummer, U. Sendler, A. Tannapfel, A. Sendler and D. Strumberg
Extended Abstract
Successful sequential antiangiogenic therapy for alveolar soft part sarcoma – a case report
B. Schultheis, G. Kummer, A. Tannapfel and D. Strumberg
Price
42.00 $
Volume 48 p. 468 - 469
Abstract
Successful sequential antiangiogenic therapy for alveolar soft part sarcoma – a case report
B. Schultheis, G. Kummer, A. Tannapfel and D. Strumberg
Extended Abstract
First-line treatment of patients with metastatic pancreatic cancer: results of a Phase II trial with S-1 (CESAR-Study group)
D. Strumberg, L. Bergmann, U. Graeven, A. Hanauske, R. Lipp, J. Schuette, B. Schultheis, P. Scigalla, P. Urrea and M.E. Scheulen
Price
42.00 $
Volume 48 p. 470 - 472
Abstract
First-line treatment of patients with metastatic pancreatic cancer: results of a Phase II trial with S-1 (CESAR-Study group)
D. Strumberg, L. Bergmann, U. Graeven, A. Hanauske, R. Lipp, J. Schuette, B. Schultheis, P. Scigalla, P. Urrea and M.E. Scheulen
Extended Abstract
Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer
D. Strumberg, B. Schultheis, M.E. Scheulen, R.A. Hilger, J. Krauss, N. Marschner, F. Lordick, F. Bach, D. Reuter, L. Edler and K. Mross
Price
42.00 $
Volume 48 p. 473 - 475
Abstract
Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer
D. Strumberg, B. Schultheis, M.E. Scheulen, R.A. Hilger, J. Krauss, N. Marschner, F. Lordick, F. Bach, D. Reuter, L. Edler and K. Mross
Original Research
Antiretroviral activity of two polyisoprenylated acylphloroglucinols, 7-epi-nemorosone and plukenetione A, isolated from Caribbean propolis
D. Díaz-Carballo, K.Ueberla, V. Kleff, S. Ergun, S. Malak, M.Freistuehler, S. Somogyi, C. Kücherer, W. Bardenheuer and D. Strumberg
Price
42.00 $
Volume 48 p. 670 - 677
Abstract
International Journal of Clinical Pharmacology and Therapeutics, Vol. 48 – No. 10/2010 (670-677)
Antiretroviral activity of two polyisoprenylated acylphloroglucinols, 7-epi-nemorosone and plukenetione A, isolated from Caribbean propolis
D. Díaz-Carballo1*, K. Ueberla2*, V. Kleff3, S. Ergun3, S. Malak4, M. Freistuehler5, S. Somogyi6, C. Kücherer6, W. Bardenheuer1 and D. Strumberg1
1Institute for Molecular Oncology and Experimental Therapeutics, Marienhospital Herne, Ruhr University of Bochum, Herne, 2Department of Molecular and Medical Virology, Ruhr University of Bochum, Bochum, 3Institute of Anatomy, 4West German Cancer Center, 5Department of Ophthalmology, University of Duisburg-Essen, School of Medicine, Essen and 6Project HIV Variability and Molecular Epidemiology/P11, Robert Koch Institute, Berlin, Germany
*The two first authors contributed equally to this work.
Objectives: Polyisoprenylated acylphloroglucinols have recently emerged as antitumoral agents. This study aims at elucidating the antiretroviral activity of two such compounds which were isolated from Caribbean propolis: 7-epi-nemorosone and plukenetione A, the structure of which is based on an adamantane moiety. Plukenetione A is for the first time shown to have antiretroviral activity. Material and methods: The isolation of both small molecules was carried out using RP-HPLC. Their antiretroviral activity was studied based on lentiviral particles produced in HEK293T cells from the SIV-based vector VLDBH; their cytotoxicity was monitored by MTT proliferation assay. The antiviral activity of 7-epi-nemorosone was studied in CEMx174-SEAP infected with the HIV-1-strain pNL4.3wt. Reverse transcriptase inhibition was determined by a standard two-step RT-PCR using MMLV RT. Results: 7-epi-nemorosone and plukenetione A were found to be potent antilentiviral agents in the employed system, inhibiting viral infection at concentrations below 1 µM/2 µM, respectively. Whereas 7-epi-nemorosone was not able to inhibit the reverse transcriptase in vitro (IC50 > 25 µM), plukenetione A effectively inhibited its enzymatic activity at an IC50 of 1.75 µM. Conclusions: Despite 7-epi-nemorosone and plukenetione A sharing some structural core elements, the mechanism of action involved in their antiretroviral activity seems to be different. We propose that 7-epi-nemorosone inhibits the viral replication by interrupting the Akt/PKB signaling cascade, as was demonstrated previously in various cell lines. Since plukenetione A effectively inhibits the enzymatic activity of MMLV reverse transcriptase at concentrations that show antilentiviral activity, we suggest that this small molecule acts by interfering with the enzyme’s catalytic site.Correspondence to:
Dr. D. Diaz-Carballo
Institut für Molekulare Onkologie und Substanzentwicklung
Marienhospital Herne
Katholische Stiftung
Ruhr-Universität Bochum
Düngelstraße 33, 44625 Herne, Germany
Email: [email protected]
Extended Abstracts
Biomarker response on exposure to sunitinib and its primary metabolite (SU12662) in metastatic colorectal cancer patients
F. Kanefendt, A. Lindauer, M. Kinzig, D. Strumberg, M.E. Scheulen, K. Mross, R. Fischer, B. Moritz, F. Sörgel and U. Jaehde
Volume 49 p. 88 - 90
Abstract
Biomarker response on exposure to sunitinib and its primary metabolite (SU12662) in metastatic colorectal cancer patients
F. Kanefendt, A. Lindauer, M. Kinzig, D. Strumberg, M.E. Scheulen, K. Mross, R. Fischer, B. Moritz, F. Sörgel and U. Jaehde
Extended Abstracts
A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment
K. Mross, M. Büchert, U. Fasol, U. Jaehde, F. Kanefendt, D. Strumberg, J. Arends, J. Hense, B. Moritz, R. Fischer and M.E. Scheulen
Volume 49 p. 96 - 98
Abstract
A preliminary report of a Phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment
K. Mross, M. Büchert, U. Fasol, U. Jaehde, F. Kanefendt, D. Strumberg, J. Arends, J. Hense, B. Moritz, R. Fischer and M.E. Scheulen
